PDS Biotechnology Corporation (PDSB): Price and Financial Metrics

PDS Biotechnology Corporation (PDSB): $5.38

0.39 (+7.82%)

POWR Rating

Component Grades













Add PDSB to Watchlist
Sign Up

Industry: Biotech



in industry

PDSB Stock Price Chart Interactive Chart >

Price chart for PDSB

PDSB Price/Volume Stats

Current price $5.38 52-week high $17.85
Prev. close $4.99 52-week low $3.47
Day low $4.85 Volume 1,234,100
Day high $5.57 Avg. volume 330,498
50-day MA $5.55 Dividend yield N/A
200-day MA $8.85 Market Cap 153.07M

PDS Biotechnology Corporation (PDSB) Company Bio

PDS Biotechnology Corporation, a clinical-stage immuno-oncology company pioneering the development of novel multifunctional immunotherapeutic products, today announced the closing of its merger with Edge Therapeutics, Inc. Following the merger, Edge will operate as “PDS Biotechnology Corporation” and the stock will trade on the Nasdaq Capital Market beginning on March 18, 2019 under the ticker symbol \

PDSB Latest News Stream

Event/Time News Detail
Loading, please wait...

PDSB Latest Social Stream

Loading social stream, please wait...

View Full PDSB Social Stream

Latest PDSB News From Around the Web

Below are the latest news stories about PDS Biotechnology Corp that investors may wish to consider to help them evaluate PDSB as an investment opportunity.

PDS Biotech posts early safety data for PDS0101, Keytruda combo in head and neck cancer

After four straight sessions of declines, the shares of PDS Biotechnology (PDSB +3.0%) are trading higher on Thursday after the clinical-stage biotech company reported initial safety data for an experimental drug combination from a mid-stage study in head and neck cancer. The Phase 2 VERSATILE-002 trial was designed to assess...

Seeking Alpha | February 24, 2022

PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium

Preliminary safety data has shown that PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer is likely safe and well tolerated without evidence of enhanced or significant toxicity FLORHAM PARK, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based o

Yahoo | February 24, 2022

PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers

PDS Biotechnology (PDSB) is based in New Jersey. For this post, I will focus on the Versamune platform of the company in oncology. PDS Biotechnology's Versamune platform leverages the body's own defense systems to prime antigen-specific CD8+ killer T cells and memory T cells. The company is combining its proprietary...

Bhavneesh Sharma on Seeking Alpha | February 22, 2022

H.C. Wainwright Sticks to Its Buy Rating for PDS Biotechnology (PDSB)

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on PDS Biotechnology (PDSB – Research Report) today and set a price target of $15.00. The company's shares closed last Tuesday at $6.96. According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of -17.4% and a 24.3% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals. PDS Biotechnology has an analyst consensus of Moderate Buy, with a price target consensus of $15.00, representing an 113.7% upside.

Catie Powers on TipRanks | February 15, 2022

PDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck Cancer

The study evaluates PDS0101 with and without KEYTRUDA® prior to surgery for HPV-associated oropharyngeal cancer FLORHAM PARK, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced the initiation of an Investigator-Initiated Trial (ITT), MC200710, for P

Yahoo | February 15, 2022

Read More 'PDSB' Stories Here

PDSB Price Returns

1-mo -0.74%
3-mo -10.48%
6-mo -43.07%
1-year -55.90%
3-year -22.03%
5-year -97.24%
YTD -33.58%
2021 278.50%
2020 -19.25%
2019 -58.72%
2018 -96.57%
2017 -25.04%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7946 seconds.